A revolutionary light-based tool is set to transform vaccine production by continuously monitoring vaccine quality during the manufacturing process. This cutting-edge technology, developed by a team of researchers at Purdue University and Merck & Co. Inc., has the potential to significantly enhance vaccine production efficiency and safety. The tool, validated through rigorous tests, measures the quality and quantity of viral particles in real-time, offering a faster and more efficient alternative to traditional methods.
The tool's unique approach is based on Raman spectroscopy, a technique that utilizes a laser to analyze a sample's molecular structure. This method is particularly advantageous for biological samples like vaccines due to its non-destructive nature and compatibility with water-based samples. Shreya Athalye, a Purdue graduate student, highlights the tool's ability to operate directly on the production line, providing results within 30 seconds, which significantly reduces time and costs.
The research team, led by Mohit Verma, combined expertise from various fields, including agricultural and biological engineering, biomedical engineering, computer science, mechanical engineering, and materials science engineering. This interdisciplinary approach ensured the tool's compatibility with industrial operations, as demonstrated by the Merck co-authors' contribution of samples and validation of the study's findings.
The tool's effectiveness was showcased through its ability to detect particles of the human cytomegalovirus (CMV), a challenging virus to vaccinate against. Researchers working on CMV vaccine development benefit from this tool's capability to analyze virus-like particles in real-time, providing valuable insights into vaccine quality and efficacy.
The team's innovation has been recognized and protected through a patent application filed by the Purdue Innovates Office of Technology Commercialization. This tool represents a significant advancement in process analytical technology (PAT), offering continuous quality control and the potential for rapid release of biologics. Verma emphasizes the tool's versatility, suggesting its applicability to various vaccine types and its role in driving the adoption of continuous manufacturing processes.
Looking ahead, the research team aims to expand the tool's capabilities by exploring its use for other viruses, vaccines, and virus-like particles. They also plan to integrate probe-based methods into continuous manufacturing processes, further enhancing the efficiency and safety of vaccine production. This groundbreaking technology is poised to revolutionize the pharmaceutical industry, ensuring faster and more reliable vaccine production.
